Liver stage

By Targets:	Cytochrome P450 (1) HSP (1) Na+/K+ ATPase (1) Parasite (11) PI3K (1) PI4K (2)
By Research Areas:	Cardiovascular Disease (1) Infection (12) Inflammation/Immunology (3)

Targets Recommended: LXR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12912

KDU691	PI4K Parasite	Infection
KDU691, an imidazopyrazine with potent anti-parasitic activity against blood stage schizonts, gametocytes and liver stages, is a Plasmodium PI4K inhibitor. KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites .

HY-118224

BPH-715

Parasite Infection

BPH-715 is a bisphosphonate, inhibits Plasmodium liver-stage growth, with an IC₅₀ of 10 μM for Plasmodium exoerythrocytic forms in HepG2 cells .

BPH-715	Parasite	Infection
BPH-715 is a bisphosphonate, inhibits Plasmodium liver-stage growth, with an IC₅₀ of 10 μM for Plasmodium exoerythrocytic forms in HepG2 cells .

HY-155536

Antimalarial agent 28	Parasite	Infection
Antimalarial agent 28 (Compound 2i) is an antiplasmodial agent. Antimalarial agent 28 inhibits P. berghei, with IC₅₀s of 0.561 μM, 0.14 μM, 4.34 μM for Liver stage, early gametocytes and ring stages of P. falciparum .

HY-155689

Antimalarial agent 30

Parasite Infection

Antimalarial agent 30 (compound 11) is an antimalarial agent that inhibits P. berghei liver stage parasite load with an EC₅₀ of 5.2 μM .
HY-155688

Antimalarial agent 29

Parasite Infection

Antimalarial agent 29 (compound 16) is an antimalarial agent that inhibits P. berghei liver stage parasite load with an EC₅₀ of 5.2 μM .

Antimalarial agent 30	Parasite	Infection
Antimalarial agent 30 (compound 11) is an antimalarial agent that inhibits P. berghei liver stage parasite load with an EC₅₀ of 5.2 μM .

Antimalarial agent 29	Parasite	Infection
Antimalarial agent 29 (compound 16) is an antimalarial agent that inhibits P. berghei liver stage parasite load with an EC₅₀ of 5.2 μM .

HY-108024A

Ganaplacide hydrochloride KAF156 hydrochloride; GNF156 hydrochloride	Parasite	Infection
Ganaplacide (KAF156) hydrochloride is a first-in-class, orally active imidazolopiperazine antimalarial agent. Ganaplacide hydrochloride is active against a broad range of Plasmodium species, including drug-resistant parasites. Ganaplacide hydrochloride is parasiticidal against both asexual and sexual blood stages as well as the liver stages of the parasite .

HY-108024

Ganaplacide KAF156; GNF156	Parasite	Infection
Ganaplacide (KAF156) is a first-in-class, orally active imidazolopiperazine antimalarial agent. Ganaplacide is active against a broad range of Plasmodium species, including drug-resistant parasites. Ganaplacide is parasiticidal against both asexual and sexual blood stages as well as the liver stages of the parasite .

HY-42682

D(+)-Galactosamine hydrochloride 1 Publications Verification D-Galactosamine hydrochloride	Others	Inflammation/Immunology
D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .

HY-150598

CHMFL-PI4K-127	PI4K PI3K	Infection
CHMFL-PI4K-127 (compound 15g) is an orally active, potent and high selective PfPI4K (Plasmodium falciparum PI4K kinase) inhibitor, with an IC₅₀ of 0.9 nM. CHMFL-PI4K-127 exhibits potent activity against 3D7 Plasmodium falciparum, with an EC₅₀ of 25.1 nM. CHMFL-PI4K-127 shows antimalaria efficacy .

HY-116444A

16-HETE	Na+/K+ ATPase	Cardiovascular Disease Inflammation/Immunology
16-HETE is arachidonic acid metabolite through subterminal hydroxylation by cytochrome P-450. 16-HETE exhibits vasodilatory and PMN inhibitory effects and serves as biomarker for early stages of non-alcoholic fatty liver disease .

HY-119046

SNX-0723	HSP Parasite	Infection
SNX-0723 is a potent Hsp90 Inhibitor with anti-Plasmodium activity. SNX-0723 shows high binding affinity for HsHsp90 and PfHsp90 with K_is of 4.4 and 47 nM, respectively. SNX-0723 inhibits liver-stage P. berghei ANKA parasites with the EC₅₀ of 3.3 μM .

HY-153547

HSP90-IN-21	Parasite	Infection Inflammation/Immunology
HSP90-IN-21 (5e) is an antiplasmodial agent, with IC₅₀ values of 0.04, 0.17 and 2.91 μM against erythrocytic stage of P. falciparum (Pf3D7 and PfDd2 strains), cytotoxicity of human liver hepatocellular carcinoma cell line (HepG2), respectively .

HY-120696

SR9186 ML368	Cytochrome P450 Parasite	Infection
SR9186 (ML368) is a potent CYP3A4 inhibitor with IC₅₀ s for inhibition of midazolam → 1′hydroxymidazolam, testosterone → 6β-hydroxytestosterone, and vincristine → vincristine M1 of 9, 4, and 38 nM, respectively. SR-9186 inhibits liver-stage development of P. falciparum to block ivermectin metabolism .

HY-162238

OSM-S-106	Parasite	Infection
OSM-S-106 is a pro-inhibitor and that inhibition of PfAsnRS occurs via enzyme-mediated production of an Asn-OSM-S-106 adduct. OSM-S-106 inhibits protein translation and activates the amino acid starvation response. OSM-S-106 exhibits selective activity against Plasmodium blood and liver stages and low intrinsic clearance by human microsomes .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library	283 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

283 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 283 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-42682

D(+)-Galactosamine hydrochloride 1 Publications Verification D-Galactosamine hydrochloride	Microorganisms Source classification Vitis vinifera cv. Zalema Plants Vitaceae Inflammation/Immunology Disease Research Fields Saccharides	Others
D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Natural
Products

Name
Email *

	Sorry, but the email address you supplied was invalid.

Liver stage

Inhibitors & Agonists

Screening Libraries

NaturalProducts

Natural
Products